D25.9: Leiomyoma of uterus, unspecified
D25.9, leiomyoma of uterus, unspecified, is listed as a covered diagnosis in 3 Medicare billing and coding articles that apply to 19 HCPCS Level II codes, including J9217 (Leuprolide acetate (for depot suspension), 7.5 mg), J1952 (Leuprolide injectable, camcevi, 1 mg), J3315 (Injection, triptorelin pamoate, 3.75 mg). 4 of these codes have a 2026 DMEPOS fee schedule amount; E0783 pays $9,917.33 to $11,667.45 (NU) depending on the state. The articles come from 2 Medicare contractors. A listed diagnosis supports medical necessity only; coverage still depends on the LCD's criteria and on documentation in the medical record.
HCPCS Level II codes with D25.9 as a covered diagnosis
| Code | Description | Medicare coverage | DMEPOS fee 2026 (state range) | Articles listing it |
|---|---|---|---|---|
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Special coverage instructions apply | — | 2 |
| J1952 | Leuprolide injectable, camcevi, 1 mg | Carrier judgment | — | 2 |
| J3315 | Injection, triptorelin pamoate, 3.75 mg | Special coverage instructions apply | — | 2 |
| J1954 | Injection, leuprolide acetate for depot suspension (lutrate depot), 7.5 mg | Carrier judgment | — | 2 |
| J9202 | Goserelin acetate implant, per 3.6 mg | Special coverage instructions apply | — | 2 |
| J1950 | Injection, leuprolide acetate (for depot suspension), per 3.75 mg | Special coverage instructions apply | — | 2 |
| J9219 | Leuprolide acetate implant, 65 mg | Special coverage instructions apply | — | 2 |
| J9225 | Histrelin implant (vantas), 50 mg | Special coverage instructions apply | — | 2 |
| J3316 | Injection, triptorelin, extended-release, 3.75 mg | Special coverage instructions apply | — | 1 |
| J9218 | Leuprolide acetate, per 1 mg | Special coverage instructions apply | — | 1 |
| E0783 | Infusion pump system, implantable, programmable (includes all components, e.g., pump, catheter, connectors, etc.) | Special coverage instructions apply | $9,917.33–$11,667.45 (NU) | 1 |
| E0786 | Implantable programmable infusion pump, replacement (excludes implantable intraspinal catheter) | Special coverage instructions apply | $10,969.75–$11,380.88 (NU) | 1 |
| E0782 | Infusion pump, implantable, non-programmable (includes all components, e.g., pump, catheter, connectors, etc.) | Special coverage instructions apply | $5,200.92–$6,118.73 (NU) | 1 |
| E0785 | Implantable intraspinal (epidural/intrathecal) catheter used with implantable infusion pump, replacement | Special coverage instructions apply | $572.38–$673.39 (KF) | 1 |
| J7999 | Compounded drug, not otherwise classified | Special coverage instructions apply | — | 1 |
| J2278 | Injection, ziconotide, 1 microgram | Special coverage instructions apply | — | 1 |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | Special coverage instructions apply | — | 1 |
| A4220 | Refill kit for implantable infusion pump | Special coverage instructions apply | — | 1 |
| J9200 | Injection, floxuridine, 500 mg | Special coverage instructions apply | — | 1 |
Medicare policy articles listing D25.9
- A59160: Billing and Coding: Luteinizing Hormone-Releasing Hormone (LHRH) Analogs (Palmetto GBA (MAC - Part A, MAC - Part B); 8 Level II codes). LCD with the same title: L39387
- A52453: Billing and Coding: Luteinizing Hormone-Releasing Hormone (LHRH) Analogs (Wellpoint Federal (MAC - Part A, MAC - Part B); 10 Level II codes). LCD with the same title: L39387
- A56695: Billing and Coding: Implantable Infusion Pump (Palmetto GBA (MAC - Part B); 9 Level II codes). LCD with the same title: L33461
A diagnosis listed as covered in a billing and coding article supports medical necessity for the article's codes; it does not guarantee payment. Coverage depends on the LCD's criteria, the contractor's jurisdiction and documentation in the medical record.
Other D25 diagnoses (Leiomyoma of uterus)
- D25.0 — Submucous leiomyoma of uterus
- D25.1 — Intramural leiomyoma of uterus
- D25.2 — Subserosal leiomyoma of uterus
Frequently asked questions
Does Medicare cover D25.9 (Leiomyoma of uterus, unspecified)?
Medicare covers items and services, not diagnoses. 3 Medicare billing and coding articles list D25.9 as a covered diagnosis for 19 HCPCS Level II codes: the diagnosis can support medical necessity for those codes, but payment still depends on the LCD's coverage criteria and the medical record.
Which HCPCS codes can be billed with ICD-10 D25.9?
The Level II codes from the policies most specific to this diagnosis are J9217 (Leuprolide acetate (for depot suspension), 7.5 mg, 2 articles); J1952 (Leuprolide injectable, camcevi, 1 mg, 2 articles); J3315 (Injection, triptorelin pamoate, 3.75 mg, 2 articles); J1954 (Injection, leuprolide acetate for depot suspension…, 2 articles); J9202 (Goserelin acetate implant, per 3.6 mg, 2 articles). Code choice depends on the item supplied; check each code's descriptor.
What does Medicare pay for equipment billed with D25.9?
Under the 2026 DMEPOS fee schedule (non-rural state fees): E0783 $9,917.33 to $11,667.45 (NU); E0786 $10,969.75 to $11,380.88 (NU); E0782 $5,200.92 to $6,118.73 (NU); E0785 $572.38 to $673.39 (KF). Medicare pays 80% of the allowed amount after the Part B deductible.
Which Medicare policy articles list D25.9?
A59160 (Billing and Coding: Luteinizing Hormone-Releasing Hormone (LHRH) Analogs); A52453 (Billing and Coding: Luteinizing Hormone-Releasing Hormone (LHRH) Analogs); A56695 (Billing and Coding: Implantable Infusion Pump).
What is ICD-10-CM code D25.9?
D25.9 is the ICD-10-CM code for leiomyoma of uterus, unspecified, in category D25 (Leiomyoma of uterus), chapter 2: Neoplasms.
Next steps
- Run a reimbursement report for a device billed under J9217
- Watch J9217 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J9217
Sources: CMS Medicare Coverage Database billing and coding articles (covered ICD-10 code lists and HCPCS links); ICD-10-CM FY2026; CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule 2026 (non-rural state fees). Not billing or legal advice.